Lonza will launch the MODA ES Software Platform, a next-generation electronic batch record execution solution
Lonza Bioscience’s MODA platform has become the standard for paperless QC microbiology for a number of global pharmaceutical and other regulated manufacturing organisations. It is a comprehensive solution for environmental, utility and product monitoring, combining automated scheduling, workflows, mobile data acquisition, device integration, and visual analytics.
Lonza is hosting a free 60-minute webinar on how to create a compelling business case for the implementation of a paperless QC testing solution. The selection of a paperless solution is only step of a longer capital expenditure (CAPEX) process, which can be difficult to navigate without a strong business case.
Jeremy Tanner, account and business development representative – Lonza Bioscience Informatics, will discuss the following topics:
Elsevier and ExactCure recently announced a collaboration to develop and offer to hospitals – without charge – drug-specific exposure models for 20 already approved medicines that are being tested as potential treatments for Covid-19.
With the world’s focus on the COVID-19 pandemic, LIMS providers are working to develop solutions tailored to assist in the testing and management of virus samples.
Researchers at Harvard Medical School (HMS) have released an open source drug discovery platform, VirtualFlow, that harnesses supercomputing power to screen potentially billions of small organic compound structures in parallel, in the hunt for promising new drug molecules.
When designing a component or system, where do you start? In days gone by, designers would literally go back to the drawing board, using their experience and expertise to develop a new concept.
Effective utilisation of computing tools is critical to both AI and HPC research, with recent projects in both fields highlighting the scientific benefit of carefully managing resources.
Advances in computer vision combined with AI computing are helping pathologists to more accurately identify subtypes of cancer - leading to better treatments for patients, explains Dan Ruderman.
